Literature DB >> 24006140

Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein.

Dace Skrastina1, Ivars Petrovskis, Rasa Petraityte, Irina Sominskaya, Velta Ose, Ilva Lieknina, Janis Bogans, Kestutis Sasnauskas, Paul Pumpens.   

Abstract

Three variants of the major rubella virus (RV) E1 protein virus-neutralizing epitope from position 214 to 285 were exposed on the hepatitis B virus (HBV) C-terminally truncated core (HBcΔ) in a virus-like particle (VLP) vector and were produced in Escherichia coli. All three chimeras demonstrated VLPs in bacterial cell lysates, but only HBcΔ-E1(245-285) demonstrated the correct VLP structure after purification. The other chimeras, HBcΔ-E1(214-285) and HBcΔ-E1(214-240), appeared after purification as non-VLP aggregates of 100 to 900 nm in diameter according to dynamic light scattering data. All three variants possessed the intrinsic antigenic activity of RV E1, since they were recognized by natural human anti-RV E1 antibodies and induced an anti-RV E1 response in mice. HBcΔ-E1(214-240) and HBcΔ-E1(245-285) can be regarded as prototypes for a putative RV vaccine because they were able to induce antibodies recognizing natural RV E1 protein in RV diagnostic kits.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24006140      PMCID: PMC3837786          DOI: 10.1128/CVI.00533-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells.

Authors:  P Cordoba; S Grutadauria; C Cuffini; M Zapata
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

Review 2.  Therapeutic vaccination for chronic diseases: a new class of drugs in sight.

Authors:  Martin F Bachmann; Mark R Dyer
Journal:  Nat Rev Drug Discov       Date:  2004-01       Impact factor: 84.694

3.  Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus.

Authors:  S A Plotkin; D Cornfeld; T H Ingalls
Journal:  Am J Dis Child       Date:  1965-10

4.  A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion.

Authors:  S A Plotkin; J Farquhar; M Katz; T H Ingalls
Journal:  Am J Epidemiol       Date:  1967-09       Impact factor: 4.897

Review 5.  HBV core particles as a carrier for B cell/T cell epitopes.

Authors:  P Pumpens; E Grens
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

6.  A recombinant rubella virus E1 glycoprotein as a rubella vaccine candidate.

Authors:  G Perrenoud; F Messerli; A-C Thierry; N Beltraminelli; P Cousin; N Fasel; V Vallet; S Demotz; M A Duchosal; C Moulon
Journal:  Vaccine       Date:  2004-12-09       Impact factor: 3.641

7.  Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae.

Authors:  K Sasnauskas; A Bulavaite; A Hale; L Jin; W A Knowles; A Gedvilaite; A Dargeviciūte; D Bartkeviciūte; A Zvirbliene; J Staniulis; D W G Brown; R Ulrich
Journal:  Intervirology       Date:  2002       Impact factor: 1.763

8.  High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae.

Authors:  Ausra Razanskiene; Jonas Schmidt; Astrid Geldmacher; Andreas Ritzi; Matthias Niedrig; Ake Lundkvist; Detlev H Krüger; Helga Meisel; Kestutis Sasnauskas; Rainer Ulrich
Journal:  J Biotechnol       Date:  2004-08-05       Impact factor: 3.307

9.  Rubella virus contains one capsid protein and three envelope glycoproteins, E1, E2a, and E2b.

Authors:  C Oker-Blom; N Kalkkinen; L Kääriäinen; R F Pettersson
Journal:  J Virol       Date:  1983-06       Impact factor: 5.103

10.  Synthesis of the measles virus nucleoprotein in yeast Pichia pastoris and Saccharomyces cerevisiae.

Authors:  Rimantas Slibinskas; Dhanraj Samuel; Alma Gedvilaite; Juozas Staniulis; Kestutis Sasnauskas
Journal:  J Biotechnol       Date:  2004-01-22       Impact factor: 3.307

View more
  5 in total

Review 1.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 2.  Protein engineering strategies for rational immunogen design.

Authors:  Timothy M Caradonna; Aaron G Schmidt
Journal:  NPJ Vaccines       Date:  2021-12-17       Impact factor: 7.344

3.  Design of a chimaeric antigen and its use in the detection of IgG antibodies against rubella virus.

Authors:  Wenyue Xing; Li Li; Jingnan Zhang; Chunli Ma; Xin Xue; Shumei Ye; Huiting Xue; Ruiping Hu; Yanhua Ma; Hong Yuan
Journal:  Virol J       Date:  2022-02-23       Impact factor: 4.099

Review 4.  Subviral particle as vaccine and vaccine platform.

Authors:  Ming Tan; Xi Jiang
Journal:  Curr Opin Virol       Date:  2014-03-21       Impact factor: 7.090

Review 5.  Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.

Authors:  Ana F Rodrigues; Hugo R Soares; Miguel R Guerreiro; Paula M Alves; Ana S Coroadinha
Journal:  Biotechnol J       Date:  2015-07-24       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.